Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Barlow's disease is characterized by excess myxomatous degenerative tissue, leaflets prolapse and/or billowing, chordal-elongation, and annular dilation. Various mitral valve repair techniques are in use. Resection techniques were conventionally performed. Non-resection techniques have been popularized; however, their efficacy in Barlow's disease is yet unclear.
Objective: This study aimed to evaluate the early outcomes of minimally invasive mitral valve repair with non-resection approach compared to resection approach in patients with Barlow's disease.
Methods: We reviewed our experience in minimally invasive mitral valve repair non-resection techniques to treat this complex mitral pathology. Between 2020 and 2024 a group of 61 patients was identified as Barlow's disease undergoing minimally invasive mitral valve repair. The diagnosis of Barlow disease was based upon preoperative echocardiography and confirmed by the surgeon's assessment during operation. Data were collected at the Medical University Center (UMC) in Ho Chi Minh City.
Results: A total of 61 patients met the inclusion criteria. Successful valve repair was achieved in 57 patients (93.4%). Among the 57 patients who underwent repair, 26 patients (45.6%) received mitral valve repair using the non-resection approach, while 31 patients (54.4%) were treated with the resection approach. The mean cardiopulmonary bypass time and aortic cross-clamp time were 146.1 ± 23.8 minutes and 84.6 ± 15.9 minutes, respectively. During the 30-day postoperative follow-up, no mortality or SAM (systolic anterior motion) complications were observed, with one case of moderate mitral regurgitation post-surgery. Additionally, no reoperations were required during the follow-up period.
Conclusion: Minimally invasive Barlow mitral valve repair has favorable 30-day postoperative outcomes. The non-resection approach is feasible and as safe as the resection approach.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12212265 | PMC |
| http://dx.doi.org/10.5455/aim.2025.33.107-111 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Salvage repair of complete aortic root detachment after Bentall procedure: a case of LVOT elongation.
Multimed Man Cardiothorac Surg
September 2025
Department of Cardiovascular Surgery, Marmara University Pendik Research and Training Hospital, Istanbul, Turkey.
Complete detachment of the aortic root following a Bentall procedure is an exceptionally rare complication. The vast majority of reported cases are secondary to prosthetic valve endocarditis or underlying vasculitis. Currently, the most reliable treatment for aortic root dehiscence-particularly in the context of prosthetic valve endocarditis-is repeat root replacement, typically via a second Bentall procedure or with the use of a homograft or allograft.
View Article and Find Full Text PDFIn-Hospital Outcomes of Simultaneous and Staged Transcatheter Aortic Valve Replacement and Endovascular Aneurysm Repair.
Catheter Cardiovasc Interv
September 2025
Division of Cardiovascular Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Introduction: Patients with aortic aneurysms are at elevated risk of rupture, dissection and death during and after transcatheter aortic valve repair (TAVR), often requiring consideration for endovascular aneurysm repair (EVAR) at the time of TAVR. However, data comparing outcomes of simultaneous versus staged TAVR-EVAR are limited.
Methods: Using the National Inpatient Sample between the years 2018 and 2021, we compared in-hospital outcomes of simultaneous and staged TAVR-EVAR.
Long Term Outcomes of Tricuspid Valve Repair or Replacement in Patients with Continuous Flow Left Ventricular Assist Devices.
J Thorac Cardiovasc Surg
September 2025
Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, NY. Electronic address:
Objective: Our objective was to determine the long-term outcomes of concomitant tricuspid valve procedures (TVP) during continuous-flow left ventricular assist device (LVAD) implantation.
Methods: We retrospectively reviewed patients who received HeartMate II or 3 from 2004 to 2023. Nine patients who had a previous TVP were excluded.
Reply: Nature versus suture: Distinct pathophysiology for left atrioventricular valve stenosis following atrioventricular septal defect repair?
J Thorac Cardiovasc Surg
September 2025
Division of Congenital Heart Surgery, Texas Children's Hospital, Houston, Tex; Department of Surgery, Baylor College of Medicine, Houston, Tex.
Correction of Tricuspid Regurgitation in Pulmonary Arterial Hypertension.
JACC Case Rep
September 2025
Department of Cardiology, Monaldi Hospital, Naples, Italy. Electronic address:
Background: Pulmonary hypertension is a contraindication to correction of tricuspid regurgitation.
Case Summary: A 75-year-old Italian woman with previous episodes of right heart failure was diagnosed with World Health Organization (WHO) functional class IV pulmonary arterial hypertension (PAH) complicated by torrential tricuspid regurgitation. After 6 months of treatment with diuretic agents, macitentan, and tadalafil, she improved to WHO functional class III, with a pulmonary vascular resistance (PVR) decreasing from 5.